Skip to content


  • Research article
  • Open Access
  • Open Peer Review

Early linear growth retardation: results of a prospective study of Zambian infants

BMC Public Health201919:61

  • Received: 31 July 2018
  • Accepted: 7 January 2019
  • Published:
Open Peer Review reports



Linear growth retardation is the most dominant nutritional problem globally. We aimed to describe linear growth trajectory among infants under 2 years of age using the WHO growth velocity standards.


This was a prospective cohort study of infants enrolled at 6 weeks of age and followed up for up to 24 months in Kamwala Urban Health Centre, Lusaka, Zambia. The study was conducted between April 2013 and March 2015. Infants were enrolled if they were 6–12 weeks of age and the mother was willing to participate voluntarily and provided informed consent. Anthropometric data were collected at scheduled clinic visits at 1 month, 2 months, 3 months, then quarterly until the infant was 24 months old. We defined linear growth velocity as the rate of change in height. We estimated linear growth velocity as the first derivative of the penalized cubic spline mixed effects model.


A total of 338 children were included in the analysis. Of these, 185 (54.7%) were female, 115 (34.1%) were born to HIV positive mothers and thus classified as HIV Exposed (HE). The mean age of children at enrollment was 1.6 months (SD = 0.15). On average, the growth velocity for 3-month length increments conditional on age were 0–3 months = 2.97 cm/3mo (95%CI = 2.69, 3.25); 3–6 months = 2.62 cm/3mo (95%CI = 2.38, 2.87); 6–9 months = 1.57 cm/3mo (95%CI = 1.43, 1.71); 9–12 months = 1.18 cm/3mo (95%CI = 1.08, 1.28); 12–15 month = 1.14 cm/3mo (95%CI = 1.02, 1.27); 15–18 months = 0.87 cm/3mo (95%CI = 0.79, 0.96); 18–21 months = 0.80 cm/3mo (95%CI = 0.72, 0.89); and 21–24 months = 0.86 cm/3mo (95%CI = 0.77, 0.96). For both boys and girls, the growth velocity in our cohort were consistently below the 3rd percentile of the WHO linear growth velocity standard. The estimated mean height and the age at which growth begins to falter were 68.6 cm (95%CI = 68.0, 69.2) and 13.6 months (95%CI = 13.2, 14.1) respectively.


We found slower rate of growth among otherwise healthy Zambian infants. The data suggests that growth retardation is universal and profound in this cohort and may have already been occurring in utero.


  • Growth retardation
  • Linear growth
  • Growth velocity
  • Growth trajectory
  • Children
  • Prospective study


Linear growth retardation is the most dominant nutritional problem globally, with approximately 22.2% or 151 million children under five reported to be stunted in 2017 [1]. Early Linear growth retardation has been shown to have long-term consequences and adversely affect adult stature and cognitive development [2, 3]. Attained growth for age, calculated as a child’s height-for-age z-score (HAZ), has been used as a measure of linear growth retardation. But this has limitations. Growth progresses at a rapidly decelerating rate from birth, reaching a near-plateau by the end of the first year, and continues to taper off gently through the second year. This is the expected trajectory of growth under conditions of adequate nutrition and psychosocial care. However, when there is a growth problem possibly due to inadequate nutrition and infections, the trajectory may change but attained growth for age is not robust enough to picking up early growth problems along this trajectory.

For this reason, we argue in this study that the human growth dynamic is complex and requires robust and clinically relevant indicators to monitor an individual’s growth trajectory. Several authors including Tanner JM 1952; Guo et al. 1991; and Roche & Himes 1980, have suggested that growth velocity can identify growth problems earlier than would have been if using attained growth [46]. They further indicated that pathogenic factors can directly affect velocity, while its effect on attained growth can be detected only after the results of growth velocity have manifested. In other words, height velocity quantifies the status of an infant at a fixed period whereas attained height indicates the results of what has happened in the past. For example, if a child has attained a height within the 50th percentile at 1-year of age, but does not grow for 1 year, at age 2 the child’s HAZ would be considered in the normal range. In contrast, his height velocity would show that there has been a stunted abnormal growth during the last 1 year. As evidenced by this example, height velocity is thus a dynamic measure, while attained growth measures are static. It is for these reasons that we considered growth velocity measure to be a more valuable tool and a superior measure for assessing infant growth compared to attained growth for age. Importantly, such growth velocity measures can lend to early identification of growth faltering, therefore making it possible to intervene promptly to avoid a reduced adult stature and related cognitive problems.

Despite this advantage however, very few studies have investigated infant growth using velocity measures. In this study, we aimed to describe the rate of growth among children under two years using the World Health Organization (WHO) growth velocity standards (WHO 2009) [7]. We also evaluated growth trajectory characteristics by determining the peak height and age at which growth begins to falter. Overall, we hope that findings from this study could provide insight into the usefulness of velocity measures as a dynamic and robust alternative for detecting early growth problems for improved care.


Study site and population

The study was undertaken at Kamwala Health Centre, a typical peri-urban clinic in Lusaka. The facility serves a large mixed population with a birth cohort more than 1400 deliveries each year. Within the premises of the clinic is the research facility, through which all under 5 clinic services were offered to the study participants. Recruitment was done while mothers come for the routine clinic visits; those with age eligible infants were invited to information sharing about the study. Motivated mothers were then invited to the research unit where informed consent was administered.

Study design and participants

This was a prospective cohort study of infants conducted between April 2013 and March 2015. Details of the design were described elsewhere [8]. Children were enrolled if, i) they were 6–12 weeks of age, the mother was willing to participate voluntarily and able to provide signed informed consent (with witness in the case of illiterate participant; ii) the infant was eligible for rotavirus vaccine (RV) immunization as per national policy (male or female infant, aged 6–12 weeks old); iii) the mother was willing to undergo study procedures, including questionnaires, human immunodeficiency virus (HIV) counselling and testing, cluster of differentiation 4 (CD4) testing and provide breast milk at enrolment; iv) the mother was willing to allow her infant to undergo study procedures, including full course RV1 vaccination, phlebotomy at enrolment and 1 month post full RV2 vaccination, and presentation to clinic for collection of stool sample when infant had diarrhoea; and v) the mother planned to remain in the area and was willing to come for scheduled visits for the duration of the study. At enrolment, socio-demographic and anthropometric data were recorded. We also collected data on mother’s HIV status. The antenatal cards were inspected to verify the HIV status of the mother. Further, anthropometric data were collected at scheduled clinic visits at 1 month, 2 months, 3 months, then quarterly until the infant was 24 months old; thus, each child was expected to attend 10 scheduled visits. Mothers were also counselled to bring back the infant when ill; such visits constituted unscheduled clinic visits. Self-reports on any diarrhoea since the previous visit were also recorded.

Statistical analysis

Summary statistics (mean and proportions) were used to describe participant’s baseline characteristics. This included infant age at first visit, gender, birthweight, mother’s age at infant birth, maternal HIV status at infant birth, and HAZ. We calculated HAZ for each baseline height measurement available for each child using the WHO child growth standards [WHO 2006] [9]. Stunting and severe stunting were defined as a HAZ < − 2 and HAZ < − 3, respectively. Based on these cut-offs, we calculated the proportion of children who were stunted and severely stunted at enrollment. We defined linear growth velocity as the rate of change in height. We included children who had at least three height measurements in the analysis.

We calculated growth velocity using two approaches. First, for each child, we calculated empirical growth velocity as the difference between two successive length or height measurements divided by the corresponding age gap. Using these values, we calculated the average 3-monthly age-specific growth velocity and 95% confidence interval (CI). The actual ages at which measurements were made were at times delayed (or advanced) compared to the target ages based on scheduled visits. This resulted in some measurement intervals being either longer or shorter than 91 days for a 3-month interval. For this reason, we corrected the actual measurement age to target age using maximum tolerable difference [7]. We adjusted standard errors for clustering of measurement within each child. The velocity and 95%CI for each age gap were presented using range plots for the entire sample and by sex. Second, we estimated linear growth velocity as the first derivative of the penalized cubic spline mixed effects model [10, 11]. This model has the functional form:
$$ {y}_{ij}=\left({b}_0+{\beta}_{0i}\right)+\left({b}_1+{\beta}_{1i}\right)x+\left({b}_2+{\beta}_{2i}\right){x}^2+\left({b}_3+{\beta}_{3i}\right){x}^3+\sum \limits_{k=1}^K\left({\mu}_k+{v}_{ki}\right)I\left(x>{K}_k\right){\left(x-{K}_k\right)}^3+{e}_{ij} $$
where \( \left({\beta}_{0i},\dots, {\beta}_{3i}\right)\sim N\left(0,\Sigma \right),{\mu}_k\sim N\left(0,{\sigma}_{\mu}^2\right),{v}_{ki}\sim N\left(0,{\sigma}_v^2\right), \) Σ is an unstructured covariance matrix, K is the total number of knots at locations x = K1, K2, … , Kk, and I(x > Kk) is an indicator function that has value 1 if the condition x > Kk is true and 0 otherwise. For fitting μk, we defined a variable that takes a value 1 to represent the whole sample as one super subject. In instances with readings that showed negative linear growth, we recoded as “no growth” by assigning the nominal value of + 0.01 to enable its inclusion in the statistical model.

We checked model adequacy using a plot of standardized residual against age. Having estimated the model, we obtained predicted height (based on both the fixed and random effects) for each child at each age. We then estimated the growth velocity as the numerical first derivative of the predicted height with respect to age. To describe the growth trajectory characteristics in terms of the peak height and age at which growth begins to decline, we identified for each child the age with the minimum absolute first derivative where the second derivative was negative. Infants who had less than three height measurements were excluded from the analysis due to the inability to calculate the rate of change of height over the duration of the study. The age and the height at that age were summarized to describe the trajectory characteristics. All analyses were performed using Stata 15 MP (StataCorp, College Station, TX, USA).


Characteristics of participants

A total of 338 children were included in the analysis. Of these, 185 (54.7%) were female, 115 (34.1%) were born to HIV positive mothers and thus classified as HIV Exposed, and 222 (65.9%) were classified as HIV Unexposed. The mean age of children at enrollment was 1.6 months (SD = 0.15). At enrolment, the prevalence of stunting was 58.6% and severe stunting was 35.8% (Table 1).
Table 1

Baseline cohort characteristics

Characteristics of participants

N = 338

Child age at first visit (months), Mean (SD)

1.6 (0.15)

Child gender (female), n (%)

185 (54.7)

Child weight at first visit (kg), Mean (SD)

4.4 (1.1)

Mother’s age at birth (years), Mean (SD)

25.7 (5.7)

Maternal HIV status, n (%)


115 (34.1)


222 (65.9)

Diarrheal episodes reported, Mean (SD)

1.1 (1.2)

Stunted at first measurement (<−2 SD), n (%)

198 (58.6)

Severely stunted at first measurement (< −3 SD), n (%)

121 (35.8)

Characteristics of linear growth trajectory

On average, the growth velocity for 3-month length increments conditional on age were 0–3 months = 2.97 cm/3mo (95%CI = 2.69, 3.25); 3–6 months = 2.62 cm/3mo (95%CI = 2.38, 2.87); 6–9 months = 1.57 cm/3mo (95%CI = 1.43, 1.71); 9–12 months = 1.18 cm/3mo (95%CI = 1.08, 1.28); 12–15 month = 1.14 cm/3mo (95%CI = 1.02, 1.27); 15–18 months = 0.87 cm/3mo (95%CI = 0.79, 0.96); 18–21 months = 0.80 cm/3mo (95%CI = 0.72, 0.89); and 21–24 months = 0.86 cm/3mo (95%CI = 0.77, 0.96) (Fig. 1). For both boys and girls, the growth velocity in our cohort were consistently below the 3rd percentile of the WHO linear growth velocity standard (Fig. 1), suggesting that growth retardation is universal and profound in our cohort.
Fig. 1
Fig. 1

Three-monthly empirical linear growth velocity. Legend: In green are the WHO linear growth velocity standard (3rd and 97th percentiles). Overall growth velocity average per 3 months’ time (a); Average growth velocity per 3 months for the boys (b); Average growth velocity per 3 months for the girls (c)

A visualization of individual growth of two children at two different percentiles and their predicted values showed our model effectively reflects individual and population growth patterns (Fig. 2b). Differences between children appeared to be largely from shifts in intercepts (Fig. 2b), with minimal differences in growth rates. This is further supported in the height velocity model in which the two individuals have almost the same rate of growth (Fig. 2d). Therefore, our model was able to effectively predict both population growth and differences between and within individuals in a population of Zambian children from a peri-urban shanty town. The estimated mean height and the age at which growth began to falter were 68.6 cm (95%CI = 68.0, 69.2) and 13.6 months (95%CI = 13.2, 14.1) (Fig. 2a). This is further supported by the near flat curve after age 13 months in Fig. 2c.
Fig. 2
Fig. 2

Observed and predicted linear growth using penalized cubic spline mixed effects model. Legend: In black are the observed growth curves and in red and blue are predicted growth curves. Observed and predicted linear growth curves for all children (a); for two individual children at different percentiles (b). Observed and predicted linear growth velocity for all children (c); for two individual children at different percentiles (d). The same children were plotted in B and D. Notice children have a different growth pattern but similar growth velocity. The knots were at 3, 4, 5, 6, 12, and 18 months


Our data showed that infant’s rate of growth were consistently below the 3rd percentile of the WHO growth velocity standards, implying inadequate nutrition even in the earlier periods of infancy. While the Zambian infants were growing at a slower rate, even by the time they entered the cohort at 6 weeks of age, the results from the present study also indicated that linear growth faltering is worst at 13.6 months of age. This is the time when nearly all the infants have completely been weaned off breastmilk.

A significant number of infants still do not benefit from optimum breastfeeding practices. Issaka et al report that in Southern Africa the overall prevalence of predominant breast feeding ranged between a lowest of 17.63% (95% CI 12.70 to 22.55) in East Africa and a highest of 46.37% (95% CI 37.22 to 55.52) in West Africa [12]. This is below the WHO/UNICEF optimum recommendation of breastfeeding for two years [1]. Breastfeeding for the first six months is crucial to child development and fundamental to the protection against illnesses. It gives infants all the nutrients they need for healthy development and contains antibodies that help protect infants from common childhood illnesses like diarrhea, and pneumonia: the two primary causes of childhood mortality worldwide [13].

While exclusive breastfeeding seems like a logical low/no cost intervention, its practice in Zambia is rather low. In our earlier study, the prevalence of exclusive breast feeding in children up to 5 months ranged between 39 and 45% [14]; and these findings are similar to what Tembo et al reported elsewhere, with a high start at 96% in the first two months of life and rapidly falling to 16% by 5 months [15]. Studies, including meta-analyses have demonstrated significant benefits of exclusive breastfeeding on diarrheal and pneumonia morbidity and mortality in children [1618]. In early infant life, there are three issues of major concern for growth: first is whether the child was born healthy without any genetically determined defects; second, is the environment and hygiene practices to safeguard against infections; and third, of relevance to this paper is nutrition that the child needs to develop. The infants in our cohort were clinically healthy and enrolled during routine immunization visits, and thus somewhat normal growth trajectory was expected. However, our findings suggest, in the very least, that their nutrition may have been inadequate.

Inadequate nutrition not only predispose to acute morbidity (particularly diarrhea and pneumonia), it causes deleterious effects to infant’s growth, eventual cognitive development and future livelihood [1719]. Thus, current global wisdom suggests that new born infants should be exclusively breastfed for the first six months of life and then additional soft feeds introduced gradually while breast feeding should continue for up to 18–21 months of age [2022]. Early introduction to solid foods is problematic as it results in low iron stores by displacing energy rich and highly bioavailable iron in breastmilk, and increase the risk of diarrheal diseases [20, 23].

In our study, all mothers self-reported exclusive breast feeding, but it is likely that there could have been over reporting, especially given WHO global reports on Zambian that only 40% of infants less than six months of age are exclusively breastfed [24]. We have previously reported gross non-compliance to the international code for marketing breastmilk supplements by the private sector; and this very likely adds to negative influences against best breastfeeding practices in Lusaka [25]. However, the downside to exclusive breastfeeding is its association with increased risk of HIV transmission from mother to child [18, 26, 27]. This is particularly important in many areas of sub-Saharan Africa like Zambia where HIV prevalence is high [28].

However, the practicality of avoiding exclusive breastfeeding remains challenging even in light of maternal HIV especially among low social economic status populations. Cost, adequacy, hygiene, water safety and ability to appropriately mix formula are well known challenges [24, 29]. Indeed a relationship has been demonstrated between poor feeding practices and incidence of diarrhea in infants [30]. One episode of acute severe gastroenteritis is known to rob the child of substantial stored nutrients such as zinc and vitamins [31, 32]. Nutrient deficiencies can rarely occur in isolation to a single micronutrient, thus it is reasonable to expect that range of key growth nutrients (including copper, iron, magnesium, selenium, zinc, vitamins A, B12, D and folate) are lost together during diarrhea. Moreover, gastroenteritis often induces both vomiting and/or loss of appetite, and thus no replenishment is occurring during that period; therefore, it is logical to suggest that diarrhea deprives the child of both stored nutrition and food intake: material needed for growth [33, 34]. Our study reported an average of 1.1 (SD = 1.2) episodes of diarrhea per child over the duration of follow up, suggesting that each child experienced at least one episode of diarrhea between the time they enroll and exited the study.

While this study has showed a slower growth in our cohort, it had some limitations. First, it was not primarily designed as an anthropometric study; rather, the parent study was focused on understanding factors that influence rotavirus vaccine taken in healthy infants [8]. Second, although common to all longitudinal studies which follow up participants over time, some children did not have anthropometric data at all time points to be included in the statistical model; fortunately, this problem was limited because there is no evidence that the missingness were systematic to cause substantial bias. Also, children in our cohort did not have length measurement recorded at birth, which may have underestimated the empirical height velocity at 0–3 mo age group. Notwithstanding these limitations, there is a clear indication that the infant population under 2 years of age possesses a growth trajectory characteristic implying that they are growing slower than expected. Indeed, while others have shown that the HAZ approach may not be entirely accurate in showing actual height gain differences [35], these data have also highlighted the importance of growth velocity as a more robust and dynamic measure of linear growth.


We found slower rate of growth among otherwise healthy Zambian infants. The data suggests that growth retardation is universal and profound in this cohort and may have already been occurring in utero. Growth retardation is a complex issue, which requires a robust and dynamic measures to detect early growth retardation among infants for improved and targeted care. Further research is needed to find best approaches to implement nutritional recommendations for the first 1000 days post-conception to prevent early growth faltering in Zambian infants.



Cluster of differentiation 4


Confidence interval


Centre for infectious diseases research in Zambia


Height-for-age z-score


Human immunodeficiency virus


Rotavirus vaccine


World Health Organization



We acknowledge the substantial contributions to this work provided by the following Research Nurses: Marcelina Hamikondo, Fridah Madyabi and Margaret Chisambi; we also thank the following individuals for administrative and logistical support for the work: Annie Chikombo, Catherine Phiri, Annie Sinyangwe, Martin Lesa and Amon Kanganja.


The research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R01AI099601. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Availability of data and materials

Data will be made available to any interested researchers upon request. The CIDRZ Ethics and Compliance Committee is responsible for approving such request. To request data access, one must write to the Secretary to the Committee/Head of Research Operations, Ms. Hope Mwanyungwi ( through the corresponding author (Samuel Bosomprah, PhD) mentioning the intended use for the data. The corresponding author will then facilitate express authorization to release the data as requested. Dataset request must include contact information, a research project title, and a description of the analysis being proposed as well as the format it is expected. The requested data should only be used for the purposes related to the original research or study. The CIDRZ Ethics and Compliance Committee will normally review all data requests within 48–72 h (Monday - Friday), and provide notification if access has been granted or additional project information is needed, before access can be granted.

Author’s contributions

R.C., and M.S. designed research; M.S., M.A., K,M-K., and H.N. conducted research; S.B., J.L.K., and O.N.C. analyzed data; and R.C., and S.B. wrote the paper. R.C., and S.B. had primary responsibility for final content. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The University of Zambia Biomedical Research Ethics Committee, University of North Carolina at Chapel Hill Institutional Review Board and the Zambian Ministry of Health approved the study. The study was conducted in accordance with the principles of the Declaration of Helsinki and in compliance with good clinical practice guidelines and is registered at with registration number NCT01886833. Written informed consent was obtained from all mothers of participating infants.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Research Division, Centre for Infectious Disease Research in Zambia, Plot # 34620, Off Alick Nkhata Road, PO Box 34681, Lusaka, Zambia
Department of Biostatistics, School of Public Health, University of Ghana, Legon, Accra, Ghana


  1. UNICEF, WHO, The World Bank Group. Levels and trends in child malnutrition: The 2018 Edition of the Joint Child Malnutrition Estimates. 2018 Contract No.: 2018 Licence: CC BY-NC-SA 3.0 IGO.Google Scholar
  2. Adair LS, Fall CH, Osmond C, et al. Associations of linear growth and relative weight gain during early life with adult health and human capital in countries of low and middle income: findings from five birth cohort studies. Lancet. 2013;382(9891):525–34.PubMedPubMed CentralView ArticleGoogle Scholar
  3. Sudfeld CR, Charles McCoy D, Danaei G, et al. Linear growth and child development in low- and middle-income countries: a meta-analysis. Pediatrics. 2015;135(5):e1266–75.PubMedView ArticleGoogle Scholar
  4. Guo S, Roche AF, Fomon SJ, et al. Reference data on gains in weight and length during the first two years of life. J Pediatr. 1991;119(3):355–62.PubMedView ArticleGoogle Scholar
  5. Roche AF, Himes JH. Incremental growth charts. Am J Clin Nutr. 1980;33(9):2041–52.PubMedView ArticleGoogle Scholar
  6. Tanner JM. The assessment of growth and development in children. Arch Dis Child. 1952;27(131):10–33.PubMedPubMed CentralView ArticleGoogle Scholar
  7. World Health Organisation. WHO Growth Standards, Growth velocity based on weight, length and head circumference. In: Methods and development; 2009. Contract No.: ISBN 978 92 4 154763 5.Google Scholar
  8. Chilengi R, Simuyandi M, Beach L, Mwila K, Becker-Dreps S, Emperador DM, et al. Association of maternal immunity with rotavirus vaccine immunogenicity in Zambian infants. PLoS One. 2016;11(3):e0150100.PubMedPubMed CentralView ArticleGoogle Scholar
  9. World Health Organisation. WHO child growth standards, Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age. In: Methods and development; 2006. Contract No: ISBN 92 4 154693 X.Google Scholar
  10. Durbán M, Harezlak J, Wand MP, et al. Simple fitting of subject-specific curves for longitudinal data. Stat Med. 2005:1153–67.Google Scholar
  11. Silverwood RJ, De Stavola BL, Cole TJ. BMI peak in infancy as a predictor for later BMI in the Uppsala family study. Int J Obes. 2009;33(33):929–37.View ArticleGoogle Scholar
  12. Issaka AI, Agho KE, Renzaho AMN. Prevalence of key breastfeeding indicators in 29 sub-Saharan African countries: a meta-analysis of demographic and health surveys (2010–2015). BMJ Open. 2017;7:e014145.PubMedPubMed CentralView ArticleGoogle Scholar
  13. Victora CG, Bahl R, Barros AJD, Franca GVA, Horton S, Krasevec J, et al. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. Lancet. 2016;387(10017):475–90.View ArticleGoogle Scholar
  14. Greenland K, Chipungu J, Curtis V, Schmidt W-P, Siwale Z, Mudenda M, et al. Multiple behaviour change intervention for diarrhoea control in Lusaka, Zambia: a cluster randomised trial. Lancet Global Health. 2016;4:e966–77.PubMedView ArticleGoogle Scholar
  15. Tembo C, Ngoma MC, Maimbolwa M, Akakandelwa A. Exclusive breast feeding practice in Zambia. Med J Zambia. 2015;42(3):124–9.Google Scholar
  16. Lamberti LM, Zakarija-Grković I, Walker CLF, Theodoratou E, Nair H, Campbell H, et al. Breastfeeding for reducing the risk of pneumonia morbidity and mortality in children under two: a systematic literature review and meta-analysis. BMC Public Health. 2013;13(Suppl 3):S18.PubMedPubMed CentralView ArticleGoogle Scholar
  17. Richard SA, McCormick BJJ, Seidman JC, Rasmussen Z, Kosek MN, Rogawski ET, et al. Relationships among common illness symptoms and the protective effect of breastfeeding in early childhood in MAL-ED: an eight-country cohort study. Am J Trop Med Hyg. 2018;98(3):904–12.PubMedPubMed CentralView ArticleGoogle Scholar
  18. WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality. Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. Lancet. 2000;355(9202):451–5.View ArticleGoogle Scholar
  19. Quigley MA, Kelly YJ, Sacker A. Breastfeeding and hospitalization for diarrheal and respiratory infection in the United Kingdom millennium cohort study. Pediatrics. 2007;119(4):e837–42.PubMedView ArticleGoogle Scholar
  20. Butte NF, Lopez-Alarcon MG, Garza C. Nutrient adequacy of exclusive breastfeeding for the term infant during the first six months of life. Geneva: World Health Organization; 2002.Google Scholar
  21. World Health Organisation. WHO Breastfeeding infographics. 2018.Google Scholar
  22. World Health Organization. United Nations Children’s fund. Guideline: updates on HIV and infant feeding: the duration of breastfeeding, and support from health services to improve feeding practices among mothers living with HIV. Geneva: World Health Organization; 2016.Google Scholar
  23. Kramer MS, Chalmers B, Hodnett ED, et al. Promotion of breastfeeding intervention trial (probit): a randomized trial in the Republic of Belarus. JAMA. 2001;285(4):413–20.PubMedView ArticleGoogle Scholar
  24. Katepa-Bwalya M, Mukonka V, Kankasa C, et al. Infants and young children feeding practices and nutritional status in two districts of Zambia. Int Breastfeed J. 2015;10:5.PubMedPubMed CentralView ArticleGoogle Scholar
  25. Funduluka P, Bosomprah S, Chilengi R, et al. Marketing of breast-milk substitutes in Zambia: evaluation of compliance to the international regulatory code. J Public Health. 2017:1–7.Google Scholar
  26. Coutsoudis A, Pillay K, Kuhn L, et al. Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa. AIDS. 2001;15(3).Google Scholar
  27. Marinda E, Humphrey JH, IIiff PJ, et al. Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr Infect Dis J. 2007;26(6):519–26.PubMedView ArticleGoogle Scholar
  28. Central Statistical Office (CSO) [Zambia]. Zambia Population-Based HIV Impact Assessment, vol. 2015; 2016. p. 57–60.Google Scholar
  29. Vaahtera M, Kulmala T, Hietanen A, et al. Breastfeeding and complementary feeding practices in rural Malawi. Acta Paediatr. 2007;90(3):328–32.View ArticleGoogle Scholar
  30. Ziyane IS. The relationship between infant feeding practices and diarrhoeal infections. J Adv Nurs. 2001;29(3):721–6.View ArticleGoogle Scholar
  31. Angelova M, Nedkova V, Nicolov A, Ivanov P, Kolarov P. Diseases aand conditions associated with zinc deficiency; serum zinc in pregnant women with reproductive failures and serum zinc in children with type I diabetes. Trakia J Sci. 2013;11(4):287–98.Google Scholar
  32. Tomkins A, Behrens R, Roy S. The role of zinc and vitamin a deficiency in diarrhoeal syndromes in developing countries. Proc Nutr Soc. 2007;52(1):131–42.View ArticleGoogle Scholar
  33. Castillo-Duran C, Vial P, Uauy R. Trace mineral balance during acute diarrhea in infants. J Pediatr. 1988;113(3):452–7.PubMedView ArticleGoogle Scholar
  34. Roth DE, L’azzerini M, Ronfani L. Commentary on ‘Oral zinc for treating diarrhoea in children’, with a response from the review authors. Evid Based Child Health Cochrane Rev J. 2009;4(4):1423–7.View ArticleGoogle Scholar
  35. Leroy JL, Ruel M, Habicht J-P, Frongillo EA. Linear growth deficit continues to accumulate beyond the first 1000 days in low- and middle-income countries: global evidence from 51 National Surveys. J Nutr. 2014;144(9):1460–6.PubMedView ArticleGoogle Scholar


© The Author(s). 2019